Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Transplantation Conditioning"" wg kryterium: Temat


Tytuł:
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges.
Autorzy:
Ahmed M; Department of Internal Medicine, University of South Dakota, Sanford School of Medicine, Sioux Falls, SD, USA.
Pollyea DA; Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 66-70. Date of Electronic Publication: 2022 Nov 02.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/epidemiology
Leukemia, Myeloid, Acute*/therapy
Hematologic Neoplasms*
Graft vs Host Disease*
Humans ; Aged ; Transplantation, Homologous ; Transplantation Conditioning/adverse effects ; Transplantation Conditioning/methods ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
Autorzy:
Lin M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Wu X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhang L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Li L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Wang X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Fu X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Sun Z; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhang X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhu L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Yu H; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Chang Y; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Nan F; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Yan J; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhou Z; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Shi C; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhang M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Li X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 605-612. Date of Electronic Publication: 2023 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Lymphoma*/diagnosis
Lymphoma*/therapy
Humans ; Etoposide/adverse effects ; Retrospective Studies ; Transplantation, Autologous ; Cytarabine/adverse effects ; Cyclophosphamide/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation Conditioning
Czasopismo naukowe
Tytuł:
Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
Autorzy:
Kumar L; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sahoo RK; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Kumar S; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Baa AK; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Tansir G; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Pathak N; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Malik PS; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sharma OD; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Mathew A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Jha A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Gupta R; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sharma A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Biswas A; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
Kumar R; Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Thulkar S; Department of Radio-diagnosis, All India Institute of Medical Sciences, New Delhi, India.
Malik S; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Dutt A; Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Pokaż więcej
Corporate Authors:
for AIIMS Myeloma Group
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 378-387. Date of Electronic Publication: 2022 Nov 23.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Melphalan/adverse effects ; Transplantation, Autologous ; Neoplasm Recurrence, Local/drug therapy ; Stem Cell Transplantation ; Treatment Outcome ; Transplantation Conditioning/adverse effects
Czasopismo naukowe
Tytuł:
Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index.
Autorzy:
Stewart T; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.
Dowling M; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Janson B; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.
Siderov J; Pharmacy Department, Austin Health, Melbourne, Australia.
Xie J; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia.
Grigg A; Department of Clinical Haematology, Austin Health, Melbourne, Australia.
Khot A; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 253-255. Date of Electronic Publication: 2022 Oct 25.
Typ publikacji:
Letter
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematologic Neoplasms*/therapy
Hematologic Neoplasms*/etiology
Acute Kidney Injury*/chemically induced
Acute Kidney Injury*/diagnosis
Graft vs Host Disease*/etiology
Humans ; Body Mass Index ; Etoposide/adverse effects ; Transplantation Conditioning/adverse effects
Opinia redakcyjna
Tytuł:
Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma.
Autorzy:
Gardenswartz A; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Mehta B; Department of Pediatrics, St. Jude Children's Research Hospital, Peoria, IL, USA.
El-Mallawany NK; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
van de Ven C; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Hochberg J; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Flower A; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
Morris E; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Harrison L; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Chu Y; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Basso J; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Gerard P; Department of Radiology, New York Medical College, Valhalla, NY, USA.
Islam H; Department of Pathology, New York Medical College, Valhalla, NY, USA.
Ayello J; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
Baxter-Lowe LA; Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, Los Angeles, CA, USA.
Cairo MS; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.; Department of Pathology, New York Medical College, Valhalla, NY, USA.; Department of Medicine, New York Medical College, Valhalla, NY, USA.; Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA.; Department of Cell Biology and Anatomy, Hematology and Stem Cell Transplantation, Valhalla, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 234-237. Date of Electronic Publication: 2022 Oct 19.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Lymphoma, Non-Hodgkin*/therapy
Humans ; Child ; Young Adult ; Adolescent ; Transplantation, Autologous ; Neoplasm Recurrence, Local ; Immunotherapy/adverse effects ; Transplantation Conditioning ; Stem Cell Transplantation
Raport
Tytuł:
Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
Autorzy:
Lu Y; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Sun RJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Zhang JP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Xu F; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Du ZC; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Tong GL; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Wang Y; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Lu DP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (13), pp. 3092-3099. Date of Electronic Publication: 2022 Sep 06.
Typ publikacji:
Journal Article
MeSH Terms:
Graft vs Host Disease*
Leukemia, Myeloid, Acute*
Hematopoietic Stem Cell Transplantation*/adverse effects
Myeloproliferative Disorders*/pathology
Humans ; Male ; Female ; Child ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged ; Retrospective Studies ; Transplantation Conditioning ; Acute Disease ; Dendritic Cells/pathology
Czasopismo naukowe
Tytuł:
Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study.
Autorzy:
Hughes MS; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sterling CH; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Varadhan R; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ambinder RF; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jones RJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sweren RJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rozati S; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bolaños-Meade J; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Luznik L; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Imus PH; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ali SA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Borrello IM; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Huff CA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jain T; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ambinder A; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
DeZern AE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gocke CB; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gladstone DE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Swinnen LJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Wagner-Johnston ND; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fuchs EJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2987-2991. Date of Electronic Publication: 2022 Aug 01.
Typ publikacji:
Journal Article
MeSH Terms:
Graft vs Host Disease*
Lymphoma, T-Cell, Cutaneous*/drug therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Retrospective Studies ; Cyclophosphamide/adverse effects ; Transplantation Conditioning
Czasopismo naukowe
Tytuł:
Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: a single center study.
Autorzy:
Lu Y; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Xiong M; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Sun RJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Zhang JP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Zhao YL; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Wei ZJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Cao XY; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Zhou JR; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Liu DY; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Lu DP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (14), pp. 3307-3316. Date of Electronic Publication: 2022 Sep 06.
Typ publikacji:
Journal Article
MeSH Terms:
Anemia, Aplastic*
Graft vs Host Disease*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Child ; Humans ; Unrelated Donors ; Retrospective Studies ; Blood Donors ; Recurrence ; Transplantation Conditioning
Czasopismo naukowe
Tytuł:
Results with allo-SCT in patients with relapsed/refractory HL treated with anti-PD-1, a multicenter retrospective cohort study: subcommittee of transplantation and cellular therapy (GATMO-TC) of the Argentinian Hematology Society (SAH).
Autorzy:
Warley F; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Berro M; Hospital Austral, Buenos Aires, Argentina.
Palmer S; Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
Castro M; Sanatorio Anchorena, Buenos Aires, Argentina.
Ferini G; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Lopez Orozco M; Hospital Privado de Córdoba, Córdoba, Argentina.
Otero V; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Arbelbide J; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Foncuberta C; Instituto Alexander Fleming, Buenos Aires, Argentina.
Yantorno S; Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina.
Basquiera A; Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (14), pp. 3508-3510. Date of Electronic Publication: 2022 Sep 16.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Hematology*
Hematopoietic Stem Cell Transplantation*/methods
Humans ; Neoplasm Recurrence, Local/therapy ; Retrospective Studies ; Transplantation Conditioning/methods ; Transplantation, Homologous
Czasopismo naukowe
Tytuł:
Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study.
Autorzy:
Kasudhan KS; Department of Clinical Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Patil AN; Department of Clinical Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Jandial A; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Khadwal A; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Prakash G; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Jain A; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Bhurani D; Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Ahmed R; Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Agrawal N; Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Singh R; Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Sachdeva MUS; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Varma N; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Das R; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Verma Attri S; Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Malhotra S; Department of Clinical Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Majhail NS; Blood and Marrow Transplant Program, Department of Hematology-Oncology, Cleveland Clinic, Cleveland, OH, USA.
Malhotra P; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Lad DP; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Nov; Vol. 63 (11), pp. 2679-2685. Date of Electronic Publication: 2022 Jun 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Transplantation Conditioning/adverse effects ; Chromatography, Liquid ; Neoplasm Recurrence, Local ; Tandem Mass Spectrometry ; Cyclophosphamide/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł:
The clinical outcomes of mixed engraftment patients treated with haploidentical stem cells combined with umbilical cord blood transplantation.
Autorzy:
Liu Y; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Qi L; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Wang T; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Zhou B; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Chen J; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Xiao J; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Fang Y; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Yang Q; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Feng Y; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Wu D; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Xu Y; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, PR China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Nov; Vol. 63 (11), pp. 2696-2700. Date of Electronic Publication: 2022 Jun 18.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Cord Blood Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Humans ; Transplantation Conditioning ; Fetal Blood
Raport
Tytuł:
Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians.
Autorzy:
Broglie L; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Friend BD; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Chhabra S; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Bupp C; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Schiller GJ; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Logan B; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Pasquini MC; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Savani B; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Stadtmauer EA; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Thakar MS; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Sorror M; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Oct; Vol. 63 (10), pp. 2507-2510. Date of Electronic Publication: 2022 May 18.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Physicians*
Adult ; Child ; Comorbidity ; Humans ; Retrospective Studies ; Transplantation Conditioning ; Transplantation, Homologous
Raport
Tytuł:
Transplantation provides superior survival high risk myeloid malignancies in older patients.
Autorzy:
Ustun C; Division of Hematology, Oncology and Cellular Therapy, Rush University, Chicago, IL, USA.
Warlick E; Syros Pharmaceuticals, Inc., Cambridge, MA, USA.
Nathan S; Division of Hematology, Oncology and Cellular Therapy, Rush University, Chicago, IL, USA.
Burns LJ; Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.
Weisdorf D; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Oct; Vol. 63 (10), pp. 2494-2498. Date of Electronic Publication: 2022 May 19.
Typ publikacji:
Letter
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Leukemia, Myeloid, Acute*
Neoplasms*
Aged ; Disease-Free Survival ; Humans ; Retrospective Studies ; Transplantation Conditioning ; Vidarabine
Opinia redakcyjna
Tytuł:
Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
Autorzy:
Horgan C; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Elmoamly S; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
McIlroy G; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Davies D; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Kaparou M; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Giles H; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Xenou E; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Kishore B; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Lovell R; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Nikolousis E; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Shankara P; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Kanellopoulos A; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (12), pp. 3075-3077. Date of Electronic Publication: 2019 May 13.
Typ publikacji:
Letter
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Alemtuzumab/*administration & dosage
Antineoplastic Agents, Immunological/*administration & dosage
Lymphoma/*pathology
Lymphoma/*therapy
Cause of Death ; Drug Resistance, Neoplasm ; Female ; Humans ; Lymphoma/mortality ; Male ; Prognosis ; Recurrence ; Retreatment ; Transplantation, Homologous ; Treatment Outcome
Opinia redakcyjna
Tytuł:
Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?
Autorzy:
Jain T; a Division of Hematology/Medical Oncology , Mayo Clinic , Phoenix , AZ , USA.
Kunze KL; b Division of Biostatistics , Mayo Clinic , Phoenix , AZ , USA.
Khetarpal BK; c Department of Internal Medicine , Mayo Clinic , Phoenix , AZ , USA.
McCallen MR; d Division of Pharmacy , Mayo Clinic , Phoenix , AZ , USA.
Betcher JA; d Division of Pharmacy , Mayo Clinic , Phoenix , AZ , USA.
Ofori HT; d Division of Pharmacy , Mayo Clinic , Phoenix , AZ , USA.
Khera N; a Division of Hematology/Medical Oncology , Mayo Clinic , Phoenix , AZ , USA.
Slack JL; a Division of Hematology/Medical Oncology , Mayo Clinic , Phoenix , AZ , USA.
Leis JF; a Division of Hematology/Medical Oncology , Mayo Clinic , Phoenix , AZ , USA.
Sproat LZ; a Division of Hematology/Medical Oncology , Mayo Clinic , Phoenix , AZ , USA.
Noel P; a Division of Hematology/Medical Oncology , Mayo Clinic , Phoenix , AZ , USA.
Palmer J; a Division of Hematology/Medical Oncology , Mayo Clinic , Phoenix , AZ , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Aug; Vol. 60 (8), pp. 2034-2041. Date of Electronic Publication: 2019 Jan 10.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Busulfan/*administration & dosage
Busulfan/*pharmacokinetics
Myeloablative Agonists/*administration & dosage
Myeloablative Agonists/*pharmacokinetics
Adult ; Aged ; Drug Monitoring ; Female ; Graft Survival ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prognosis ; Recurrence ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.
Autorzy:
Harada K; a Department of Hematology and Oncology , Tokai University School of Medicine , Isehara , Japan.
Yanada M; b Department of Hematology and Cell Therapy , Aichi Cancer Center , Nagoya , Japan.
Machida S; a Department of Hematology and Oncology , Tokai University School of Medicine , Isehara , Japan.
Kanamori H; c Department of Hematology , Kanagawa Cancer Center , Yokohama , Japan.
Onizuka M; a Department of Hematology and Oncology , Tokai University School of Medicine , Isehara , Japan.
Ozawa Y; d Department of Hematology , Japanese Red Cross Nagoya First Hospital , Nagoya , Japan.
Kobayashi H; e Department of Hematology , Nagano Red Cross Hospital , Nagano , Japan.
Sawa M; f Department of Hematology and Oncology , Anjo Kosei Hospital , Anjo , Japan.
Katayama Y; g Department of Hematology , Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital , Hiroshima , Japan.
Ohashi K; h Hematology Division , Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital , Tokyo , Japan.
Kanda J; i Department of Hematology and Oncology , Graduate School of Medicine, Kyoto University , Kyoto , Japan.
Ichinohe T; j Department of Hematology and Oncology , Research Institute for Radiation Biology and Medicine, Hiroshima University , Hiroshima , Japan.
Atsuta Y; k Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.; l Department of Healthcare Administration , Nagoya University Graduate School of Medicine , Nagoya , Japan.
Yano S; m Division of Clinical Oncology and Hematology , The Jikei University School of Medicine , Tokyo , Japan.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Jun; Vol. 60 (6), pp. 1493-1502. Date of Electronic Publication: 2018 Nov 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Chemoradiotherapy/*methods
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*therapy
Melphalan/*administration & dosage
Neoplasm Recurrence, Local/*epidemiology
Transplantation Conditioning/*methods
Whole-Body Irradiation/*methods
Adult ; Age Factors ; Aged ; Chemoradiotherapy/adverse effects ; Chemoradiotherapy/statistics & numerical data ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Japan/epidemiology ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Neoplasm Recurrence, Local/prevention & control ; Prognosis ; Registries/statistics & numerical data ; Retrospective Studies ; Transplantation Conditioning/adverse effects ; Transplantation, Homologous/adverse effects ; Transplantation, Homologous/methods ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives ; Whole-Body Irradiation/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł:
Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation.
Autorzy:
Lin A; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brown S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maloy M; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ruiz JD; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Devlin S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
DeRespiris L; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Proli A; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jakubowski AA; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Papadopoulos EB; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Sauter CS; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Tamari R; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Castro-Malaspina H; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Shaffer B; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Barker J; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Perales MA; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Giralt SA; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Gyurkocza B; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1686-1693. Date of Electronic Publication: 2022 Feb 10.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Graft vs Host Disease*/diagnosis
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Adrenal Cortex Hormones/adverse effects ; Humans ; Immunosuppressive Agents/adverse effects ; Methotrexate/adverse effects ; Mycophenolic Acid/adverse effects ; Transplantation Conditioning/methods
Czasopismo naukowe
Tytuł:
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
Autorzy:
Speziali C; a Department of Medical Oncology and Haematology , CancerCare Manitoba , Winnipeg , MB , Canada.; b Section of Hematology/Oncology, Department of Internal Medicine , University of Manitoba , Winnipeg , MB , Canada.
Daly A; c Departments of Medicine and Oncology , Foothills Medical Centre , Calgary , AB , Canada.; d Tom Baker Cancer Centre , Calgary , AB , Canada.
Abuhaleeqa M; e Leukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer Agency , Vancouver , BC , Canada.; f Department of Medicine, Division of Hematology, University of British Columbia , Vancouver , BC , Canada.
Nitta J; e Leukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer Agency , Vancouver , BC , Canada.; f Department of Medicine, Division of Hematology, University of British Columbia , Vancouver , BC , Canada.
Abou Mourad Y; e Leukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer Agency , Vancouver , BC , Canada.; f Department of Medicine, Division of Hematology, University of British Columbia , Vancouver , BC , Canada.
Seftel MD; a Department of Medical Oncology and Haematology , CancerCare Manitoba , Winnipeg , MB , Canada.; b Section of Hematology/Oncology, Department of Internal Medicine , University of Manitoba , Winnipeg , MB , Canada.
Paulson K; a Department of Medical Oncology and Haematology , CancerCare Manitoba , Winnipeg , MB , Canada.; b Section of Hematology/Oncology, Department of Internal Medicine , University of Manitoba , Winnipeg , MB , Canada.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Mar; Vol. 60 (3), pp. 639-648. Date of Electronic Publication: 2018 Aug 30.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Whole-Body Irradiation*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Busulfan/administration & dosage ; Combined Modality Therapy ; Female ; Graft vs Host Disease/etiology ; Humans ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Prognosis ; Recurrence ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives ; Young Adult
Czasopismo naukowe
Tytuł:
Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study.
Autorzy:
Lu Y; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Zhao YL; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Xiong M; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Sun RJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Cao XY; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Wei ZJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Lu DP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 May; Vol. 63 (5), pp. 1211-1219. Date of Electronic Publication: 2021 Dec 16.
Typ publikacji:
Journal Article
MeSH Terms:
Graft vs Host Disease*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Hemoglobinuria, Paroxysmal*/diagnosis
Hemoglobinuria, Paroxysmal*/therapy
Pancytopenia*/etiology
Bone Marrow Failure Disorders ; Humans ; Retrospective Studies ; Transplantation Conditioning ; Unrelated Donors
Czasopismo naukowe
Tytuł:
Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.
Autorzy:
Lebel E; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Vainstein V; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Ashkenazi M; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Zimran E; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Stepensky P; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Grisariu S; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Avni B; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 May; Vol. 63 (5), pp. 1144-1151. Date of Electronic Publication: 2021 Dec 29.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Hodgkin Disease*/pathology
Lymphoma*/drug therapy
Lymphoma*/therapy
Lymphoma, Non-Hodgkin*/pathology
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Autografts ; Cytarabine ; Etoposide/adverse effects ; Humans ; Melphalan/adverse effects ; Neoplasm Recurrence, Local/drug therapy ; Neutrophils/pathology ; Prospective Studies ; Transplantation Conditioning/methods ; Transplantation, Autologous/methods
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies